AL Amyloidosis Clinical Trial

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

Summary

This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.

View Full Description

Full Description

This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with suspected cardiac amyloidosis or with a putative diagnosis of cardiac amyloidosis but with remaining diagnostic uncertainty (e.g., unclear etiology or cardiac manifestation) or patients with diagnosis of amyloidosis but unclear cardiac involvement.

The diagnostic efficacy of the visual and quantitative assessments of [18F]florbetaben PET images for diagnosis of cardiac AL Amyloidosis will be determined by comparison to the standard of truth (SoT) obtained through standard of care clinical diagnosis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Males and females age ≥18 years
Able to understand, sign and date written informed consent
Written informed consent must be obtained before any assessment is performed
Subjects being considered for a possible diagnosis of cardiac amyloidosis by

1. One of the following conditions:

Established systemic amyloidosis without proven cardiac involvement,
Known plasma cell dyscrasia (MGUS, multiple myeloma),
Pathological free light chain levels in urine or serum,
Presence of heart failure with preserved ejection fraction

2. AND one of the following parameters, indicative of cardiac manifestation:

Mean (left ventricular (LV) wall + septum) thickness >12mm as measured by echocardiography in absence of other known cause of left ventricular hypertrophy (LVH),
NT-proBNP >335 ng/L
Planned diagnostic procedure to establish diagnosis and cardiac involvement (e.g., endomyocardial biopsy or extracardiac biopsy in conjunction with cardiac magnetic resonance imaging/echocardiography or bone scintigraphy)
Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or post-menopausal for at least 1 year (no menses for 12 months without an alternative medical cause). If they are of child-bearing potential, they must commit to use of a highly effective contraceptive measure for at least one week following the PET scan
Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception for a minimum of 90 days following the PET scan
Male subjects must commit to not donate sperm for a minimum of 90 days after the PET scan

Exclusion Criteria:

Any known allergic reactions or hypersensitivity towards any compound of the study drug
Severe hepatic impairment (AST/ALT >5 x ULN; bilirubin >3 x ULN)
Inability to lay flat for up to 60 min
Pregnant, lactating or breastfeeding
Unwilling and/or unable to cooperate with study procedures
Having been administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study

Study is for people with:

AL Amyloidosis

Phase:

Phase 3

Estimated Enrollment:

200

Study ID:

NCT05184088

Recruitment Status:

Recruiting

Sponsor:

Life Molecular Imaging GmbH

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 14 Locations for this study

See Locations Near You

St Luke's Hospital
Kansas City Kansas, 64111, United States
University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States
University of Pittsburgh
Pittsburgh Pennsylvania, 15213, United States
University of Augsburg
Augsburg , 86156, Germany
Charite Berlin
Berlin , 13353, Germany
University of Essen
Essen , 45147, Germany
HOPA Hamburg
Hamburg , 22767, Germany
University of Heidelberg
Heidelberg , 69120, Germany
University of Würzburg
Würzburg , 97080, Germany
Hospital University Bellvitge
Barcelona , 08907, Spain
Hospital University Puerta de Hierro
Madrid , 28222, Spain
Clínica Universidad de Navarra
Pamplona , 31008, Spain
University of Salamanca
Salamanca , 37007, Spain
Royal Free Hospital
London , NW3 2, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

AL Amyloidosis

Phase:

Phase 3

Estimated Enrollment:

200

Study ID:

NCT05184088

Recruitment Status:

Recruiting

Sponsor:


Life Molecular Imaging GmbH

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.